Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study


Ilki C. D. , Gunduz T. , Kurtuncu M. , Yapici Z. , Sencer S. , Eraksoy M.

TURKISH JOURNAL OF NEUROLOGY, vol.26, no.1, pp.34-38, 2020 (Journal Indexed in ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.4274/tnd.galenos.2019.77010
  • Title of Journal : TURKISH JOURNAL OF NEUROLOGY
  • Page Numbers: pp.34-38

Abstract

Objective: Clinical studies in childhood multiple sclerosis (MS) are very limited compared with adults. Although first-line injection therapies are well tolerated in this patient group, there are difficulties in the long-term treatment of patients due to the difficulty and adverse effects of injections for children. Oral therapies are better tolerated for use and adverse effects compared with injection therapies. This study aimed to evaluate the clinical features and treatment outcomes of patients aged under 18 years with relapsing-remitting MS (RAMS) who received fingolimod treatment.